What is the official website of SEQENS ?

The official website of SEQENS is http://www.seqens.com.

What is SEQENS's cybersecurity risk score?

SEQENS has an AI-generated cybersecurity risk score of 759 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has SEQENS experienced?

According to Rankiteo, SEQENS currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has SEQENS been affected by any supply chain cyber incidents ?

According to Rankiteo, SEQENS has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does SEQENS have SOC 2 Type 1 certification ?

According to Rankiteo, SEQENS is not certified under SOC 2 Type 1.

Does SEQENS have SOC 2 Type 2 certification ?

According to Rankiteo, SEQENS does not hold a SOC 2 Type 2 certification.

Does SEQENS comply with GDPR ?

According to Rankiteo, SEQENS is not listed as GDPR compliant.

Does SEQENS have PCI DSS certification ?

According to Rankiteo, SEQENS does not currently maintain PCI DSS compliance.

Does SEQENS comply with HIPAA ?

According to Rankiteo, SEQENS is not compliant with HIPAA regulations.

Does SEQENS have ISO 27001 certification ?

According to Rankiteo,SEQENS is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does SEQENS operate in ?

SEQENS operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does SEQENS have ?

SEQENS employs approximately 1,115 people worldwide.

Does SEQENS own any subsidiaries ?

SEQENS presently has no subsidiaries across any sectors.

How many LinkedIn followers does SEQENS have ?

SEQENS's official LinkedIn profile has approximately 48,226 followers.

What is the NAICS classification code for SEQENS ?

SEQENS is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does SEQENS have a Crunchbase profile ?

No, SEQENS does not have a profile on Crunchbase.

Does SEQENS have a LinkedIn profile ?

Yes, SEQENS maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/seqens.

How many cybersecurity incidents has SEQENS experienced ?

As of August 19, 2026, Rankiteo reports that SEQENS has experienced 1 cybersecurity incidents.

How many peer or competitor companies does SEQENS have ?

SEQENS has an estimated 5,728 peer or competitor companies worldwide.

What types of cybersecurity incidents has SEQENS faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

SEQENS

Boost Score +25 with badge (5 left)

759

/1000

Fair

784

/1000

Fair

SEQENS Vendor Cyber Rating & Cyber Score

seqens.com

Add Your Compliance Badge

SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. The group generates a revenue of 1 MM€ and operates 16 manufacturing plants and 9 R&D centers in Europe, North America and Asia. 3,300 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers. SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.

SEQENS A.I CyberSecurity Scoring

Scoring History

SEQENS

SEQENS CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

SEQENS

Ransomware

100

8/2021

SI-553072525

Loading…

A.I.

SEQENS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for SEQENS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for SEQENS in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for SEQENS in 2026.

Incident Types SEQENS vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for SEQENS in 2026.

Incident History - SEQENS (X = Date, Y = Severity)

Loading…

SUBSIDIARY

SEQENS Subsidiaries

SEQENS

Pharmaceutical Manufacturing

Website: http://www.seqens.com

Company Size: 1,115

SK Capital PartnersFinancial Services

Apotex Inc.Pharmaceutical Manufacturing

Apotex Pharmachem Inc.Pharmaceutical Manufacturing

ApobiologixBiotechnology Research

Apotex Inc. - QuébecPharmaceutical Manufacturing

ArchromaChemical Manufacturing

Color Atlas by ArchromaTextilherstellung

HeubachChemical Manufacturing

Ascend Performance MaterialsChemical Manufacturing

Acteev By AscendTextile Manufacturing

SI GroupChemical Manufacturing

Careers at SI GroupChemical Manufacturing

TPC GroupChemical Manufacturing

Valtris Specialty ChemicalsChemical Manufacturing

ChamplorFood and Beverage Manufacturing

GEON Performance SolutionsPlastics Manufacturing

Isolatek InternationalWholesale Building Materials

Tilley DistributionChemical Manufacturing

EcopolPackaging and Containers Manufacturing

Noramco™Pharmaceutical Manufacturing

Luxium SolutionsManufacturing

Lacerta Group, LLC.Packaging and Containers Manufacturing

DeltechChemical Manufacturing

INEOS CalabrianChemical Manufacturing

Woodstock Sterile SolutionsPharmaceutical Manufacturing

J&K IngredientsFood and Beverage Manufacturing

Foremark Performance ChemicalsChemical Manufacturing

Florachem CorporationChemical Manufacturing

VanDeMark Chemical IncChemical Manufacturing

CanlakChemical Manufacturing

SEQENS Pharmaceutical SolutionsPharmaceutical Manufacturing

SEQENS Personal CarePersonal Care Product Manufacturing

Loading…

SEQENS Similar Companies

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Loading…

NEWS

SEQENS CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 20, 2025 07:00 AM

Hackers are turning DNA sequencing into a biosecurity nightmare

Explore rising cybersecurity threats facing next-generation DNA sequencing and why urgent interdisciplinary action is needed now.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-66591

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in David Lingren Media LIbrary Assistant allows Stored XSS. This issue affects Media LIbrary Assistant: from n/a through 3.39.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

2.3

REFERENCES

https://patchstack.com/database/wordpress/plugin/media-library-assistant/vulnerability/wordpress-media-library-assistant-plugin-3-39-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-66589

SUMMARY

Missing Authorization vulnerability in Kings Plugins B2BKing allows Exploiting Incorrectly Configured Access Control Security Levels. This issue affects B2BKing: from n/a through 5.2.30.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://patchstack.com/database/wordpress/plugin/b2bking-wholesale-for-woocommerce/vulnerability/wordpress-b2bking-plugin-5-2-30-broken-access-control-vulnerability?_s_id=cve

CVE-2026-27365

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in PublishPress PublishPress Series allows Stored XSS. This issue affects PublishPress Series: from n/a through 2.17.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

1.7

REFERENCES

https://patchstack.com/database/wordpress/plugin/organize-series/vulnerability/wordpress-publishpress-series-plugin-2-17-0-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-73974

SUMMARY

linuxfabrik-lib provides Python modules for database access, caching, shell execution, and API integrations, and Linuxfabrik Monitoring Plugins uses its shared testing helper across check plugins. Prior to linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0, lib.lftest.test() treated the first or second element of a --test CSV argument as a filesystem path and returned the file contents as simulated standard output or standard error without path confinement. The hidden but production-accessible --test argument was accepted by sudo-authorized plugins, so an attacker controlling the nagios or icinga account could use check-plugins/deb-updates/deb-updates with its default QUERY=1 to disclose every line of a root-readable file. Approximately 22 other plugins exposed filtered content or a root file existence and readability oracle through the same helper, while check-plugins/network-bonding/network-bonding and check-plugins/openstack-swift-stat/openstack-swift-stat had direct read paths that bypassed the helper. The library fix confines fixture reads to the invoking plugin's unit-test directory and refuses unsafe anchors, and the plugin fix routes the two bypasses through that helper. These issues are fixed in linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-73973

SUMMARY

Linuxfabrik Monitoring Plugins provides monitoring plugins for Icinga, Nagios, and related systems. Prior to version 7.0.0, check-plugins/logfile/logfile accepted a free-form --filename path and opened it as root when invoked through the shipped nagios or icinga sudoers allowlist, without confining the resolved path to /var/log. An attacker who controls the monitoring account can select a root-readable file such as /etc/shadow and use --warning-regex . while leaving SUPPRESS_OUTPUT false, causing each nonempty line to be collected in warn_matches and returned through lib.base.oao(). The vulnerable flow passes the expanded scan_path directly to open(), and neither real-path containment nor an allowlist protects the sink. The same fix also confines mysql-logfile and openvpn-client-list paths, allows only documented log roots, and resolves symlinks and parent-directory traversal before checking containment. This issue is fixed in version 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…